This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bioterrorism  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2002;288:2681.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2002;51:1024-1026

In December 2000, the Advisory Committee on Immunization Practices (ACIP) released its recommendations for using anthrax vaccine in the United States.¹ Because of recent terrorist attacks involving the intentional exposure of U.S. civilians to Bacillus anthracis spores and concerns that the current anthrax vaccine supply is limited, ACIP developed supplemental recommendations on using anthrax vaccine in response to terrorism. These recommendations supplement the previous ACIP statement in three areas: use of anthrax vaccine for pre-exposure vaccination in the U.S. civilian population, the prevention of anthrax by postexposure prophylaxis (PEP), and recommendations for additional research related to using antimicrobial agents and anthrax vaccine for preventing anthrax.

Use of Anthrax Vaccine for Pre-Exposure Vaccination

In December 2001, the U.S. Department of Health and Human Services obtained a limited supply of anthrax vaccine (BioThrax [formerly Anthrax Vaccine Adsorbed (AVA)], BioPort, Lansing, Michigan), allowing ACIP to reconsider using anthrax vaccine in the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Birth Defects among Infants Born to Women Who Received Anthrax Vaccine in Pregnancy
Ryan et al.
Am J Epidemiol 2008;168:434-442.
ABSTRACT | FULL TEXT